Basic Information | Post buying leads | Suppliers | Cas Database |
Name |
Sulfadiazine |
EINECS | 200-685-8 |
CAS No. | 68-35-9 | Density | 1.496 g/cm3 |
PSA | 106.35000 | LogP | 2.59460 |
Solubility | Very slightly soluble in cold water | Melting Point |
254 °C |
Formula | C10H10N4O2S | Boiling Point | 512.6 °C at 760 mmHg |
Molecular Weight | 250.281 | Flash Point | 263.8 °C |
Transport Information | N/A | Appearance | White to slightly yellow crystalline powder |
Safety | 26-36 | Risk Codes | 22-36/37/38-42/43 |
Molecular Structure | Hazard Symbols | Xn,Xi | |
Synonyms |
Sulfanilamide,N1-2(1H)-pyrimidinylidene- (6CI);Sulfanilamide, N1-2-pyrimidinyl- (8CI);2-(4-Aminobenzenesulfonylamino)pyrimidine;2-(p-Aminobenzenesulfonamido)pyrimidin;4-Amino-N-(2-pyrimidinyl)benzenesulfonamide;4-[[(Pyrimidin-2-yl)amino]sulfonyl]aniline;Adiazine;Cremodiazine;Debenal;Deltazina;Di-Azo-Mul;Diazin;Diazovit;Diazyl;Lipo-Levazine;Liquadiazine;N1-2-Pyrimidylsulfanilamide;Neazine;Pirimal;Pyrimal;RP 2616;Spofadrizine;Sterazine;Sulfadiazine;Sulfapirimidin;Sulfazin (Russian pharmaceutical);Sulfazine;Sulfolex;Sulphadiazine E;Sulfadiazine (SD); |
Article Data | 29 |
Conditions | Yield |
---|---|
Stage #1: 2-aminopyrimidine; p-acetylaminobenzenesulfonyl chloride With calcium carbonate In toluene at 20 - 65℃; Stage #2: With water; sodium hydroxide In toluene at 100 - 115℃; Stage #3: With acetic acid pH=5 - 5.5; Reagent/catalyst; | 98.5% |
Stage #1: 2-aminopyrimidine; p-acetylaminobenzenesulfonyl chloride With pyridine In tetrahydrofuran at 20℃; for 6h; Inert atmosphere; Stage #2: With sodium hydroxide for 2h; Inert atmosphere; Reflux; | 65% |
Stage #1: 2-aminopyrimidine; p-acetylaminobenzenesulfonyl chloride With pyridine In tetrahydrofuran at 20℃; for 6h; Stage #2: With sodium hydroxide for 2h; Reflux; |
N-benzylidene-sulfanilic acid pyrimidin-2-ylamide
sulfadiazine
Conditions | Yield |
---|---|
With water In acetone at 20℃; for 0.666667h; Irradiation; | 98% |
Conditions | Yield |
---|---|
In ethanol at 100℃; for 4h; Green chemistry; | 91% |
Conditions | Yield |
---|---|
In butan-1-ol at 100℃; for 4h; Green chemistry; | 90.8% |
Malondialdehyde
1-amino-4-({[amino(imino)methyl]amino}sulfonyl)benzene
sulfadiazine
Conditions | Yield |
---|---|
With sodium methylate In methanol at 65℃; for 2h; Temperature; | 89% |
Conditions | Yield |
---|---|
In methanol at 100℃; for 4h; Temperature; Green chemistry; | 87% |
2-aminopyrimidine
3-(4-acetylamino-benzenesulfonyl)-2-benzenesulfonylimino-2,3-dihydro-thiazole
sulfadiazine
Conditions | Yield |
---|---|
und anschliessenden Erhitzen mit wss. NaOH; |
Conditions | Yield |
---|---|
und anschliessenden Erhitzen mit wss. NaOH; |
Conditions | Yield |
---|---|
With potassium carbonate |
Conditions | Yield |
---|---|
With potassium carbonate |
Reported in EPA TSCA Inventory.
The Sulfadiazine, with the CAS registry number 68-35-9, is also known as Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-. It belongs to the product categories of Antibiotics for Research and Experimental Use; Biochemistry; Sulfonamides (Antibiotics for Research and Experimental Use). Its EINECS registry number is 200-685-8. This chemical's molecular formula is C10H10N4O2S and molecular weight is 250.277. Its IUPAC name is called 4-amino-N-pyrimidin-2-ylbenzenesulfonamide. Side effects reported for sulfadiazine include: nausea, upset stomach, loss of appetite, and dizziness. This chemical's classification codes are Anti-infective Agents; Antibacterial; Antiparasitic Agents; Antiprotozoal agents; Coccidiostats; Drug / Therapeutic Agent; Human Data; Reproductive Effect.
Physical properties of Sulfadiazine: (1)ACD/LogP: -0.12; (2)ACD/LogD (pH 5.5): -0.13; (3)ACD/LogD (pH 7.4): -0.66; (4)ACD/BCF (pH 5.5): 1; (5)ACD/BCF (pH 7.4): 1; (6)ACD/KOC (pH 5.5): 19.93; (7)ACD/KOC (pH 7.4): 5.87; (8)#H bond acceptors: 6; (9)#H bond donors: 3; (10)#Freely Rotating Bonds: 2; (11)Index of Refraction: 1.679; (12)Molar Refractivity: 63.14 cm3; (13)Molar Volume: 167.2 cm3; (14)Surface Tension: 82.6 dyne/cm; (15)Density: 1.496 g/cm3; (16)Flash Point: 263.8 °C; (17)Enthalpy of Vaporization: 78.38 kJ/mol; (18)Boiling Point: 512.6 °C at 760 mmHg; (19)Vapour Pressure: 1.28E-10 mmHg at 25°C.
Preparation of Sulfadiazine: this chemical can be prepared by chaff iodate and nitro metformin. This reaction will need reagents acetyl groups benzene sulfo-chloride and pyridine.
Uses of Sulfadiazine: It eliminates bacteria that cause infections by stopping the production of folic acid inside the bacterial cell, and is commonly used to treat urinary tract infections (UTIs). In combination, sulfadiazine and pyrimethamine, can be used to treat toxoplasmosis, a disease caused by Toxoplasma gondii.
When you are using this chemical, please be cautious about it as the following:
This chemical may cause inflammation to the skin or other mucous membranes. It is irritating to eyes, respiratory system and skin. In case of contact with eyes, you should rinse immediately with plenty of water and seek medical advice. Whenever you will contact it, please wear suitable protective clothing.
You can still convert the following datas into molecular structure:
(1)Canonical SMILES: C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N
(2)InChI: InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,; (3)16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
(4)InChIKey: SEEPANYCNGTZFQ-UHFFFAOYSA-N
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
child | TDLo | oral | 1800mg/kg/5D- (1800mg/kg) | KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" KIDNEY, URETER, AND BLADDER: HEMATURIA ENDOCRINE: HYPOGLYCEMIA | Postgraduate Medical Journal. Vol. 53, Pg. 103, 1977. |
child | TDLo | unreported | 138mg/kg (138mg/kg) | BEHAVIORAL: GENERAL ANESTHETIC KIDNEY, URETER, AND BLADDER: HEMATURIA KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED | Postgraduate Medical Journal. Vol. 53, Pg. 103, 1977. |
dog | LD | oral | > 5gm/kg (5000mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 79, Pg. 354, 1943. | |
man | TDLo | oral | 229mg/kg/8D-I (229mg/kg) | GASTROINTESTINAL: OTHER CHANGES KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED | Israel Journal of Medical Sciences. Vol. 6, Pg. 561, 1970. |
mouse | LD50 | intraperitoneal | 750mg/kg (750mg/kg) | "Handbook of Analytical Toxicology," Sunshine, I., ed., Cleveland, OH, Chemical Rubber Co., 1969Vol. -, Pg. 109, 1969. | |
mouse | LD50 | intravenous | 180mg/kg (180mg/kg) | U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals. Vol. NX#03347, | |
mouse | LD50 | oral | 1500mg/kg (1500mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 571, 1971. | |
mouse | LD50 | subcutaneous | 1600mg/kg (1600mg/kg) | Drugs in Japan Vol. 6, Pg. 386, 1982. | |
rat | LD50 | intravenous | 880mg/kg (880mg/kg) | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 211, Pg. 367, 1950. | |
rat | LDLo | intraperitoneal | 446mg/kg (446mg/kg) | Klinische Wochenscrift. Vol. 27, Pg. 449, 1949 |